Eef Schimmelpennink, Lenz Therapeutics CEO
November 15, 2023 07:44 AM ESTUpdated 08:38 AM
Deals

Graphite Bio hands Nas­daq spot to pres­by­opia biotech Lenz Ther­a­peu­tics as PhI­II read­outs loom

Kyle LaHucik

Senior Reporter

Nine months af­ter throw­ing in the tow­el on its gene edit­ing pro­gram for sick­le cell dis­ease, Graphite Bio said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Charles Riv­er to close ‘15 small­er sites’ as de­mand for ear­ly re­search de­clines

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Athi­ra gives up on lead Alzheimer’s drug, switch­es tack to ALS

Nkar­ta drops an­oth­er can­cer pro­gram as it leans in­to au­toim­mune dis­ease

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times